-
2023-508531-30-00
4
2024-03-25
grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2023-504735-41-00
5
2024-03-05
Moderately to Severely Active Crohn's Disease
-
2022-502351-60-00
4
2024-02-22
Patients having a HER2-amplified metastatic breast cancer with evoluti
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2024-514101-65-00
4
2023-12-21
Multiple Myeloma
-
2023-504555-27-00
5
2023-11-28
Myelodysplastic syndrome (MDS)
-
2024-517220-19-00
5
2023-10-31
Crohn's ileal disease
-
2024-515317-18-00
4
2023-10-26
Adults with a rhizarthrosis stage DELL 1 to 3
-
2022-501057-36-00
5
2023-10-24
ANCA-associated vasculitis
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2024-513669-38-00
5
2023-05-17
Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
-
2024-514929-33-00
5
2023-03-27
PANCREATIC FISTULA
-
2024-514351-14-00
4
2023-02-20
Pure cell red aplasia by major ABO mismatch after allogeneic hematopoi
-
2023-506239-14-00
5
2022-12-13
Crohn’s Disease
-
2023-503335-18-00
1
2022-07-29
Chronic myeloid leukemia
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2024-512969-14-01
4
2022-05-02
Patient who underwent Allogeneic hematopoietic stem cell
transplantati
-
2024-511609-44-00
10
2022-02-03
Rectum cancer
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2023-509254-58-00
7
2021-05-31
Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Ly
-
2024-513427-17-00
6
2021-05-20
Well controlled severe allergic asthma
-
2024-515019-22-00
5
2021-02-26
Septic shock
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma